Saturday, October 31, 2026

Aspen Group Stock Soars 31% In 21 Sessions

Aspen Group Stock Soars 31% In 21 Sessions

(VIANEWS) - Aspen Group (NASDAQ: ASPU) shares have seen an incredible 31.43% surge, rising from EUR0.17 to EUR0.23. After experiencing two consecutive sessions of losses prior to this surge, Aspen Group managed to outperform the overall market decline which totalled 0.35% to EUR16,216.07 with 21.31% below its 52-week high at EUR0.26.

About Aspen Group

Aspen Group, Inc. is an education technology company providing online higher education services in the US. Operating two universities - Aspen University and United States University - which offer bachelor's, master's, and doctoral degree programs across nursing & health sciences, business & technology, arts & sciences, education fields. As of April 30 2022 Aspen Group had 13,334 degree-seeking students enrolled. Established in 1987 and based out of New York City.

Yearly Analysis

Aspen Group (ASPG:FRA) stock price currently trades at EUR0.23; significantly below its 52-week high of EUR0.26 but higher than its low point of EUR0.03 which may cause concern among investors; however it should be remembered that stock prices can be affected by various factors, including market conditions and company specific news; so investors must conduct further investigation before making their final investment decisions.

Technical Analysis

Aspen Group stock has been performing exceptionally well, currently above both its 50-day and 200-day moving averages of EUR0.18 and EUR0.16, signalling an upward trajectory in recent times. This bodes well for future performance! However, it should be noted that Aspen Group's current trading volume of 1090 is significantly lower than their annual average volume of 31,626 despite positive momentum - suggesting it may be experiencing low trading activity due to investors lacking interest or uncertainty about this stock. Aspen Group has displayed a steady, predictable intraday volatility pattern. Over the last week, month and quarter, its average volatility averages were respectively 1.344%, 1.144% and 5.955% with its highest amplitude at 3.822% for last week, 5.955% for month and 5.05% for quarter. Overall, Aspen Group's stock performance appears strong with values surpassing both moving averages and consistent volatility patterns. Investors should pay particular attention to trading volume levels since low trading activity could indicate lack of trust in its future prospects.

Quarter Analysis

Sales Growth Aspen Group's sales growth shows a decrease of 24% for this quarter and 29.3% in the next. This represents an alarmingly steep decrease, which could impact its financial performance negatively. Revenue Growth Quarter-on-Quarter revenue growth for the twelve trailing months decreased by 19% year-on-year to total 58.83M, which indicates a drop in revenues over time that may impact its financial health.

Equity Analysis

Earnings Per Share Aspen Group reported a trailing 12-month EPS of EUR-0.38, indicating a negative earnings per share figure and potentially signalling that it may not be making enough revenue to cover its expenses and may be facing financial strain. Return on Equity With an annualized return on equity of -12.95%, this company's return on equity indicates it is not producing sufficient profits relative to shareholder's equity. This could indicate they may be struggling to generate profits and not effectively using its equity resources.

More news about Aspen Group (ASPU).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com